Platform

Platform Introduction

Real Model-Driven Discovery and Validation of Real Targets

In the era of cancer precision medicine, it is urgent for target discovery to move from the traditional "gene mutation annotation" to "functional true drive". TRICBIO has built a multi-dimensional target discovery system that integrates organoid modeling, functional genome screening, in situ TRiC platform and AI data interpretation. The platform runs through the whole process from model construction, target intervention to mechanism analysis, and can realize the discovery and verification of high-value targets from "0 to 1", which is widely applicable to the development of small molecules, ADC, antibodies, PROTAC and other drug types.

Based on the air-liquid interface (ALI) technology, the organoid 2.0 model can retain the immune cells, fibroblasts and matrix structure in the tumor tissue, and realize the reduction of the primary microenvironment of the tumor. Compared with traditional organoids, 2.0 models can be used to simulate immune drug effects and microenvironmental interference reactions, which are closer to real treatment scenarios, and are important models for accurate drug evaluation and screening.

Organoid 2.0 Modeling Platform

Derived from ALI technology at Stanford University, an organoid system with a native immune microenvironment

• Support multi-cancer organ modeling (>1500 PDO)

• Based on the air-liquid interface (ALI) culture method, the original structure of the tumor tissue, immune cells, matrix components

• Provide one-stop outsourcing services such as 1.0 and 2.0 modeling services, drug sensitivity testing, freezer construction, imaging and pathological analysis

Applications:

• Tumor drug sensitivity testing • Personalized medication guidance

• Immune efficacy evaluation • Model construction.

TRICBIO supports two types of screening tools, CRISPR and shRNA, which can cover a variety of regulation methods such as overexpression/activation/inhibition/knockout, and is suitable for 2D cells, 3D organoids, animal models and other systems. The screening process, from library design and packaging to model infection and processing, to sequencing and target scoring analysis, is standardized to provide high-throughput and high-confidence support for target screening.

Functional Genomics Screening Platform

Moving from "Mutant or Not" to "Functional or Not"

• Integrated CRISPR-Cas9 and shRNA interference system to support positive/negative screening and target enrichment analysis

• Can be screened in two-dimensional cell lines, three-dimensional organoids and animal models

• Support whole genome library, prefabricated classification sub-library, customized sub-library, library co-construction and foundry services.

Applications:

• Novel target discovery

• Tumor recurrence and metastasis

• Synthetic lethality

• Drug resistance mechanism research

• Antibody/Small molecule screening support

TRiC (Tumor Repertoire in situ Capture) platform is an in situ target screening system independently developed by Zevey Bio, which realizes direct target intervention and functional evaluation in primary tumor tissues, organoids and animal models. The platform retains the original state of the tumor microenvironment, and after high-throughput interference/activation, combined with biological information analysis, can quickly output candidate targets and their mechanisms of action, especially suitable for target discovery in complex tumor backgrounds.

TRiC In Situ Target Screening Platform

Industry-exclusive platform for direct discovery of functional targets in primary tumor tissues/organoids/animal models

• Preserve the original appearance and microenvironment of the organization, and accurately reduce the background of the treatment response.

• Systematic enrichment screening deconvolution association analysis data mining.

• Can be extended to immunotherapy, drug resistance, recurrence, metastasis, rare mutations and other complex pathological background

Provides full-process service or module customization: from library screening to information analysis and target evaluation report.

Multi-Group AI Intelligent Analysis System

From "data" to "mechanism" to make functional screening results more explanatory

• High-throughput data integration: RNA-seq, WES, proteome, spatial transcriptome, epigenomics, etc.

• Target evaluation model construction, combined with AI algorithm to optimize high-value targets.

• Build a mechanism network map, drug effect prediction model, to assist in transformation decision-making.

Applications:

• Multi-channel mechanism research

• Data-driven drug development strategy optimization

Core Application Scenarios

Novel Target Discovery and Validation

Drug Sensitivity Testing

Drug Resistance

Immunotherapy Response Prediction

Drug Combination Discovery

Personalized Precision Medicine

Integration Platform

• Support the target discovery path from "0 to 1"

• The platform is connected with disease sample resources to accurately restore the disease state.

• Suitable for multi-type innovative drug development, including small molecules, antibodies, ADCs, PROTACs, CAR-T, TILs, etc.

• One-stop support for the whole process of experimental data mechanism verification

If you have technical cooperation, model co-construction, screening projects or customization needs, please contact our scientific team.

We look forward to providing you with professional, efficient and transformation-oriented technical service support.

For customized research/target development services, please contact TRICBIO Team. We will provide you with professional, efficient and reliable one-stop support.

Contact Us